Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
Inventors
FEDERICO, Maurizio Paolo Maria
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.
Core Innovation
The invention relates to a nucleic acid vaccine platform in which muscle cells are transfected with DNA encoding an exosome-anchoring fusion protein. The encoded fusion protein comprises human HIV-1 Nef protein with mutations 3C, 153L, and 177G fused at its C-terminus to an immunogenic antigen, so that engineered endogenous exosomes are generated.
The engineered endogenous exosomes are stated to cross-present antigen and induce antigen-specific CD8+ CTL responses in a subject. The platform is further described as producing CTL immune responses without detectable anti-antibody responses against the immunogenic antigen, and as breaking tolerance in a HER2/neu transgenic mouse model.
The approach supports broad selection of immunogenic antigens for CTL induction, including viral and tumor/tumor-associated antigens. It also includes experimental evidence of engineered exosome detection, cross-priming dependence on exosome biogenesis, CTL activity, and therapeutic effects including tumor growth inhibition or delay.
Claims Coverage
Independent claim clm-00001 covers inducing a therapeutically effective CTL immune response via intramuscular administration of a nucleic acid vaccine encoding a specific exosome-anchoring fusion protein. The claim contains 2 main inventive elements.
Nucleic acid vaccine encoding mutated Nef fusion to an immunogenic antigen
A nucleic acid expression vector comprising a polynucleotide encoding a fusion protein in which human HIV-1 Nef with mutations 3C, 153L and 177G is fused at its C-terminus to an immunogenic antigen.
Muscle administration to induce therapeutically effective CTL immune response
Administering the nucleic acid vaccine to the muscle of a subject, optionally with one or more pharmaceutically acceptable excipient and/or adjuvant, wherein the administration induces a therapeutically effective CTL immune response.
Overall, the independent claim is directed to muscle administration of a nucleic acid vaccine encoding a mutated human HIV-1 Nef (3C, 153L, 177G) exosome-anchoring fusion at the C-terminus to an immunogenic antigen, with the resulting induction of a therapeutically effective CTL immune response.
Stated Advantages
Induces antigen-specific CD8+ CTL responses.
Produces CTL immune responses without detectable anti-antibody responses against the immunogenic antigen.
Breaks tolerance in HER2/neu transgenic mice.
Inhibits or delays tumor growth.
Documented Applications
Inducing a therapeutically effective cytotoxic lymphocyte (CTL) immune response in a subject by administering a nucleic acid vaccine to the muscle.
Use of the method with a broad set of immunogenic antigens including viral antigens (e.g., HPV E6/E7, HIV antigens, Ebola antigens, West Nile NS3, HBV/HCV proteins, influenza NP/M1) and tumor/tumor-associated antigens (e.g., melanoma MAGE-A3/MART-1, Her2/neu, HoxB7).
Interested in licensing this patent?